FDA Approves VAXELIS Combo Vaccine Despite Infant Mortality (6 in 1)

Armed with Knowledge

FDA Approves VAXELIS Combo Vaccine Despite Infant Mortality

Last week, the U.S. Food and Drug Administration (FDA) approved VAXELIS, a new 6-in-1 combo vaccine. The new drug, produced as a collaborative effort by pharmaceutical giants Merck and Sanofi, claims to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae (H. influenzae) type b.

The vaccine has been approved for infants as young as 6 weeks old and will be administered in a series of 3 doses between 6 weeks and 4 months of age.

READ MORE….

adsorbed on aluminium phosphate adsorbed on amorphous aluminium hydroxyphosphate sulfate The vaccine may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin and polymyxin B which are used during the manufacturing process

The post FDA Approves VAXELIS Combo Vaccine Despite Infant Mortality (6 in 1) appeared first on Vaccine Liberation Army.